Showing 5481-5490 of 7902 results for "".
- Stelara Receives FDA Approval To Treat Active Psoriatic Arthritishttps://practicaldermatology.com/news/20130923-stelara_receives_fda_approval_to_treat_active_psoriatic_arthritis/2459457/The FDA recently approved Stelara (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis. For the treatment of psoriatic arthritis, Stelara is administered as a 45
- Alma® Lasers Kicks of Nationwide Roadshow, Practice Success Seminarshttps://practicaldermatology.com/news/20130917-alma_kicks_off_nationwide_roadshow/2459458/Alma® Lasers kicks off its Practice for Success series of seminars this week. Seminars, led by aesthetic professionals, will focus on marketing strategies proven to grow aesthetic practices. There are also opportunities for hands-on participat
- Exuviance Launches Age Less Everyday Daily Moisturizerhttps://practicaldermatology.com/news/20130912-exuviance_launches_age_less_everydaydaily_moisturizer/2459462/NeoStrata Company, Inc., recently introduced Exuviance Age Less Everyday, a daily moisturizer formulated to correct the signs of aging for skin that is dry, sensitive, or easily impacted by everyday stressors. Exuviance Age Less Everyday is formulated w
- FDA Approves Botox Cosmetic to Treat Crow's Feet Lines in Adultshttps://practicaldermatology.com/news/20130912-fda_approves_botox_cosmetic_to_treat_crows_feet_lines_in_adults/2459463/The FDA recently approved Botox Cosmetic (onabotulinumtoxinA) for an additional indication to temporarily treat moderate to severe lateral canthal lines. Allergan's
- VelaShape III Platform from Syneron Receives FDA Clearance for Abdominal Circumferential Reductionhttps://practicaldermatology.com/news/20130911-synerons_velashape_iii_platform_receives_fda_clearance_for_abdominal_circumferential_reduction/2459464/The VelaShape III, Syneron's new non-invasive body shaping platform, recently received FDA clearance and CE mark approval for temporary reduction in circumference of the abdomen. The VelaShape III
- Caliber Imaging & Diagnostics Introduces VivaScope 1500 Multilaser Systemhttps://practicaldermatology.com/news/20130910-caliber_imaging__diagnostics_introduces_vivascope_1500_multilaser_system/2459465/Caliber Imaging & Diagnostics, formerly Lucid, Inc., recently introduced the VivaScope 1500 Multilaser system, cellular imaging devices that give researchers the option of a painless, no
- Advanced Dermatology & Cosmetic Surgery, (ADCS Clinics) Acquires Lakeland Dermatology, Inc.https://practicaldermatology.com/news/20130906-advanced_dermatology__cosmetic_surgery_adcs_clinics_acquires_lakeland_dermatology_inc/2459467/ADCS Clinics (“ADCS”) has completed the acquisition of Dr. David W. Murray's, dermatology practice located in Lakeland, Florida. Dr. Murray is Board-Certified - trained at the University of Oregon Health Sciences Center and did his residency at the Naval Hospital in San Diego. He spent 11 years in a
- Anacor Submits NDA, Presents Data for Tavaborolehttps://practicaldermatology.com/news/20130830-anacor_submits_nda_presents_data_for_tavaborole/2459469/Anacor Pharmaceuticals has submitted an NDA to the FDA for for Tavaborole, its drug candidate for the topical treatment of onychomycosis. The company recently reported data presented at this summer's 2013 APMA Annual Scientific Meeting. Findings s
- Sensus Healthcare Appoints Dr. Mark Nestor as Clinical Directorhttps://practicaldermatology.com/news/20130830-sensus_healthcare_appoints_dr_mark_nestor_as_clinical_director/2459470/Mark Nestor, MD, PhD has been appointed as Clinical Director of Sensus Healthcare. Dr. Nestor will lead the company's efforts in the areas of training, education, and clinical research as Se
- Agenda Set for 2013 Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20130830-agenda_set_for_2013_cosmetic_surgery_forum/2459471/The 2013 Cosmetic Surgery Forum, taking place from December 5 – 7 at the Aria Resort and Casino in Las Vegas, has recently unveiled its agenda. According to course director Joel Schlessinger, MD, this year's meeting promises offer attendees a host of new sessions on injectables and newer methods of